# Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs)

Source: https://welltoldgrants.com/grants/rfa-mh-27-150-advancing-real-world-effectiveness-evidence-for-rapid-acting/  
Official notice: https://www.grants.gov/search-results-detail/363875

> National Institutes of Health plans to offer grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expects to make about 3 awards worth $20.0 million in total. It is a forecast: the notice is expected around October 10, 2026, with applications due around November 13, 2026.

| Field | Value |
|---|---|
| Opportunity number | RFA-MH-27-150 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | expected November 13, 2026 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | 3 |
| Total funding | $20.0 million |
| Cost sharing | not required |
| Assistance Listings | 93.242 |

## Who can apply

- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;

## What the grant funds

The National Institute of Mental Health (NIMH) intends to publish a Notice of Funding Opportunity (NOFO) to support the development of a research network to study rapid-acting psychotropic interventional drugs (RAPIDs), such as ketamine, esketamine, psilocybin, and other emerging treatments for serious mental illnesses. Preliminary studies suggest that RAPIDs can produce clinically meaningful improvements in mental health outcomes, in some cases following a single dose. However, important questions remain regarding their effectiveness, safety, durability of benefit, and implementation in routine clinical practice. As these interventions move toward broader use, rigorous real-world evidence is needed to identify how RAPIDs can be delivered safely, effectively, and sustainably across diverse patients, providers, and health care settings. The primary goal of this NOFO is to generate actionable evidence on the clinical effectiveness, safety, and implementation of RAPIDs. The resulting evidence from this study will help determine how RAPIDs can be safely and effectively integrated into clinical care and may inform future approaches to health care delivery.

## Questions people ask

### Who can apply for Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs)?

National Institutes of Health accepts applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs)?

Expected deadline November 13, 2026. Confirm the date and time in the official notice on Grants.gov.

### How much funding is available?

About $20.0 million in total across about 3 awards.